| Ticker Symbol: | VRTX |
|---|---|
| Exchange: | NASD |
| Contact Info: | 130 Waverly Street Cambridge MA 02139-4242 617 444-6100 |
| CEO/President: | Joshua S. Boger Ph.D. |
| Industry: | Medical - Biomedical / Standard Industry Code: 2834 |
| Description: | Vertex Pharmaceuticals Inc. discovers, develops and markets small molecule drugs that address major unmet medical needs. The company has eight drug candidates in clinical development to treat viral diseases, inflammation, cancer, autoimmune diseases and neurological disorders. Vertex has created its pipeline using a proprietary information-based approach to drug design that integrates multiple technologies in biology, chemistry and biophysics aimed at increasing the speed and success rate of drug discovery. (PRESS RELEASE) |
| Shares Outstanding: | 148,620 (000) | Market Value: | 3,511,880 ($000) |
|---|---|---|---|
| Percentage of Inst.Shareholders: | 98.57% | Number of Inst.Shareholders: | 4.10% |
| Last Quarter Sales: | 31.61 ($Mil.) | Last Quarter Net Income: | -130.04 ($Mil.) |
| Last Quarter EPS: | -0.93 | P/E Ratio: | 0 |
| Most Recent Earnings: | -0.93 on 10/27/08 | Earnings Per Share: | -2.97 |
| Most Recent Split: | 2-1 on 08/24/00 | Annual Dividend Rate: | 0 |
| Most Recent Dividend: | Annual Dividend Yield: | 0% |

| AMGEN INC. | +12.10 | 56.34 | |
| GILEAD SCIENCES | -8.20 | 45.55 | |
| CELGENE CORPORA | -16.00 | 52.78 | |
| GENENTECH INC | -1.40 | 73.65 | |
| GENZYME CORPORA | -21.90 | 61.21 |
